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Abstract
Objective: Determine the prevalence and compare some 
genetic markers involved in addictive behavior in a group 
of addicts to derivative of coca (cocaine/crack) or heroin 
and a control group of non-addicted people matched for 
gender, age and ethnicity.
Methods:  A 120 addicts and 120 non-addicts Colombian 
male were surveyed and genotyped for 18 polymorphism 
of the OPRM1, DRD2, DRD4,  SLC6A3, SLC6A4, ABCB1, 
DβH and CYP2B6 genes. For the identification of alleles 
markers were used mini-sequencing and fragment 
multiplex PCR techniques; ethnicity of cases and controls 
was analyzed with 61 AIMs.  
Results: The age of onset use of heroin or coca derivatives 
(cocaine/crack) was 16.5±6 years and 99.2% of them 
consume several illicit drugs. It showed that controls 
and addicts belong to the same ethnic group. Significant 
differences between addicts and controls in relation to 
schooling, marital status, social security family history of 
substance abuse (p <0.001), Int8-VNTR SLC6A3 gene (p= 
0.015) and SNP 3435C>T ABCB1 gene (p= 0.001) were 
found. 
Conclusion: The present results indicate that the VNTR-
6R polymorphism of the gene SLC6A3 and the genotype 
3435CC in the ABCB1 gene, are both associated with 
addictive behavior to heroin or cocaine.
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Drug addiction is a devastating disease characterized by compulsive 
search and consumption of drugs, despite their physical, 
psychological and social consequences. The characterization 
of the problem and identification of the variables involved in 
addictive behavior should be a priority in the health plans of any 
community that suffers the scourge of drug addiction; especially 
in Colombia, where the problem is critical because this country 
has had an important role in the production, export, import and 
consumption of illicit drugs. This situation overflows the field of 
health and creates serious problems with corruption and violence 
arising from illicit trade1. 
Resumen    
Objetivo: Determinar la prevalencia y comparar 
marcadores genéticos involucrados en conducta adictiva 
en un grupo de adictos a cocaína/crack o heroína y en un 
grupo control de no adictos apareados por género, edad y 
etnicidad.
Métodos: 120 varones adictos y 120 no adictos fueron 
encuestados y genotipificados para 18 alelos de los genes 
OPRM1, DβH, DRD2, DRD4, SLC6A3, SLC6A4, ABCB1 
y CYP2B6. Para la identificación de los diferentes alelos se 
utilizaron las técnicas de minisecuenciación y multiplex 
PCR. La etnicidad de casos y controles fue analizada con 
61 marcadores ancestro-informativos.
Resultados: La edad de inicio en el consumo de heroína 
o derivados de la coca fue de 16.5±6 años y el 99.2% 
de ellos eran policonsumidores. Los controles y los 
adictos pertenecen al mismo grupo étnico. Diferencias 
significativas entre adictos y controles fueron encontradas 
en relación con escolaridad (p <0.001), estado civil (p 
<0.001), seguridad social (p<0.001) e historia familiar de 
drogadicción (p <0.001), genotipo int8-VNTR del gen 
SLC6A3 (p= 0.015)  y al SNP 3435C>T (rs1045642) del gen 
ABCB1(p= 0.001).
Conclusión: Los resultados indican que  el polimorfismo 
VNTR-6R del gen SLC6A3 y el genotipo 3435CC en el gen 
ABCB1, están asociados con conducta adictiva a heroína 
o cocaína. 
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The use of drugs with addictive potential can evolve from 
controlled social use through the abuse, up to the drug dependence, 
characterized by the search and the compulsive use and 
dysfunctional. The probability that a person makes the transition 
from occasional use to addiction depends on factors related to 
the drug itself (such as availability and toxicological properties), 
the exposed individual (such as their genetic background and 
psychiatric morbidity) and the environment (such as family 
relationships and socio-economic stressors)2. Independently of 
the psychoactive substance used, the addictive disorders share 
clinical features that suggest the existence of common molecular 
basis: 1) preferred start in adolescence, chronic course with 
remissions and exacerbations and strong tendency to relapse; 
2) narrowing of behavioral repertoire and continue attitude of 
seeking and use despite harmful consequences; 3) progressive 
condition, 4) tolerance; 5) suppression syndrome. The proposed 
neurochemistry models converge in that all drugs of abuse are 
addictive because its consumption increased dopaminergic tone 
in “gratification centers”, where after a long period eventually 
cause adaptations the order biochemical, physiological and 
structural, involving the mesocorticolimbic system, therefore its 
proposed that the addiction is caused by an imbalance between the 
“impulsive” system (limbic system), which governs the search for 
pleasure, and the “reflective” system (frontal lobe) which executive 
function is to regulate and control the impulsive system. Chronic 
exposure to drugs of abuse induces in the patient a neuroplasticity 
that allows the patient an aberrant form of learning along with a 
behavior increasingly rigid in terms of search and consumption 
of the addictive drug, at expense of more adaptive and flexible 
responses3.
Current evidence indicates that polymorphisms of genes encoding 
the following proteins involved in metabolism, distribution or 
mechanism of action of cocaine and heroin contribute to both the 
susceptibility and the response to drugs used in the treatment of 
addiction caused by these drugs2 (a) µ-opioid receptor. Encoded 
by the OPRM1 gene, mediates the major effects of opioids and 
some of its polymorphisms have been associated with drug abuse2; 
(b) D2 and D4 dopamine receptors. Dopaminergic stimulation 
of the brain at critical sites is mediated, among others, these two 
receptor subtypes. Certain polymorphisms of the DRD2 and 
DRD4 genes are involved in the abuse of multiple substances, age 
of onset in the psycho-stimulants abuse and dependence4; (c) 
Dopamine transporter (DAT). The DAT is responsible for active 
reuptake of DA from the synapse and is the main regulator of 
dopaminergic neurotransmission in brain regions involved in 
reward and reinforcement. Pleasurable and addictive effects of 
cocaine are mediated by the blockage of DAT, and some mutant 
alleles of the SLC6A3 gene, which encodes this transporter, have 
been associated with cocaine dependence5 ;(d) Dopamine beta 
hydroxylase (DβH) The DβH found inside synaptic vesicles 
of monoaminergic pathways and catalyzes the conversion of 
dopamine to norepinephrine. DβH polymorphisms appear to 
influence the effects of cocaine and other stimulants6; (e) Serotonin 
transporter. Serotonin is another neurotransmitter in the CNS 
actively recaptured from the synaptic vesicle to the presynaptic 
terminal by its specific transporter, which is encoded by the gene 
SLC6A4, whose polymorphisms have also been associated with 
various addictions7; (f) P-glycoprotein (P-gp). 
Is a key transporter in the disposition of drugs in the CNS, some 
polymorphisms of ABCB1 gene, which encodes P-gp, produce a 
poor transporter that modifies the distribution of psychoactive 
drugs in the CNS and other tissues8 ; (g) CYP2B6 enzyme. 
Among the drug-metabolizing genes,CYP2B6 is one of the most 
polymorphic and certain allelic variants divide the population into 
rapid and slow metabolizers of drugs such as methadone, used in 
the treatment of heroin dependence9.
In summary, no conclusive evidence yet pointing to a group 
of genes as largely responsible for susceptibility to starting of 
psychoactive drugs and scaling in drug addiction and response to 
therapies. Identification of these genetic markers will allow early 
detection of people at risk in order to take appropriate preventive 
action and offer better treatment options for those who suffer from 
this lamentable condition.  In this study we proposed to determine 
the prevalence and compare some genetic markers involved in 
addictive behavior in a group of addicts to derivative of coca 
(cocaine/crack) or heroin and a control group of non-addicted 
people matched for gender, age and ethnicity.
Materials and Methods
Volunteers. The case group consisted of 120 men dependent on 
derivatives of coca (cocaine/crack) and/or heroin, which were 
internal in 13 rehabilitation centers in Pereira city (Colombia). 
Inclusion criteria were: 1) age between 16 and 60 years, 2) 
diagnosis of coca derivatives (cocaine/crack)  and/or heroin 
dependence, according to the DSM-IV, among the cases could 
be addicted to other drugs of abuse legal (alcohol, nicotine) or 
illegal, 3) accept the requirements of the study, including the 
signing of informed consent. Excluded were individuals with 
chronic neurological disease, cognitive impairment, history of 
psychiatric illness (dementia or psychosis), epilepsy. The control 
group was composed of 120 men with no history of drug abuse or 
dependence of any kind (including alcohol and nicotine), chronic 
use of psychotropic medication, psychosis, suicide attempts or 
epilepsy, matched to cases for age, gender and ethnicity. There 
was not related participants in this study. To avoid problems 
of population stratification between cases and controls was 
determined the degree of ethnicity of both groups.
After each participant was informed about the objectives of 
this study and signed the informed/consent form, oral mucosa 
sample was taken for genotyping. During personal interview the 
participants were surveyed and the form designed for the purposes 
of study, based on the instrument Addiction Severity Index (ASI), 
was filled. This protocol was approved by the Bioethics Committee 
of the Faculty of Health Sciences of the Universidad Tecnológica 
de Pereira (UTP) and rehabilitation centers authorities where 
patients were treated.
Single nucleotide polymorphism (SNP) genotyping: After 
extraction of genomic DNA obtained from oral mucosa cells, 
using the Chelex method from FTA cards, we proceeded to the 
amplification of two fragments of the OPRM1 gene, one of the 
DβH gene, one of the DRD2 gene, three of the ABCB1 gene and 
six CYP2B6 gene, in which will be studied including SNP. The PCR 
fragments was carried out in a total volume of 10 µL, containing 
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1-10 ng de genomic DNA, 1X Qiagen Multiplex PCR Master Mix 
(QIAGEN) and 0.2-0.6 µM of each of the primers (Table 1), with 
following conditions:  an initial denaturation step of 95° C for 10 
min, followed by 35 cycles of 94° C for 1 min, 60° C for 90 s and 
72° C for 50 s, followed by a final extension of 72° C for 7 min. 
Excess primers and nucleotides were removed by adding 2 µL of 
ExoSAP-IT (Amersham Pharmacia) according to manufacturer´s 
instructions. Using this pre-amplification product as template, 
were carried out reactions for the detection of SNPs using the 
mini-sequencing method (SBE, single base extension). SBE 
reactions were performed in a total volume of 6 µL, containing 
2 µL of pre-amplification product, 2.5 µL of SNaPshot Reaction 
Mix (Applied Biosystems), 1.5 µL of the SBE primer mixture with 
concentration of 0.2 µM (Table 1), and amplification for 25 cycles 
of  96° C for 10 s, 50° C for 5 s and 60° C for 30 s. Excess nucleotide 
was removed by adding 1 U of SAP (Shrimp Alkaline Phosphatase, 
Amersham Pharmacia) according to manufacturer´s instructions. 
1 µL of the SBE reaction product were analyzed by capillary 
electrophoresis (CE) using the ABI Prims 3100-Avant Genetic 
Analyzers (Applied Biosystems) with run module SNP36-POP-4. 
The data were analyzed using the GeneMapper v3.2 software 
(Applied Biosystems). The presence of the polymorphisms was 
confirmed by direct sequencing and, ABCB1 polymorphism was 
confirmed again by Real Time PCR.
Variable Number Tandem Repeats (VNTR) and InDel Genotyping. 
VNTR and InDel typing of the gene DRD4, SLC6A3 and SLC6A4 
were conducted in multiplex PCR. PCR fragments was carried out 
in a total volume of 10 µL, which contain 1-10 ng of genomic DNA, 
1X Qiagen Multiplex PCR Master Mix (Qiagen), 1X Q-Solution 
(Qiagen) and 0.2 mu of each forward and reverse primers of these 
markers (Table 1). 
The amplified fragments were carried out with the following 
parameters: an initial denaturation step for 15 min at 95° C, 
followed by 40 cycles of  94° C for 1 min, 60° C for 1 min and 
72° C for 1 min with final extension at 72° C for 7 min. 1 µL of 
the amplified product was analyzed by CE using the ABI Prims 
3100-Avant  Genetic Analyzers (Applied Biosystems) with run 
module FragmentAnalysis-36-POP-4. The data were analyzed 
by using the GeneMapper v3.2 software (Applied Biosystems). 
The presence of the polymorphisms was confirmed by direct 
sequencing.
Ancestry-informative markers 
(AIMs) Genotyping. 61 markers of ancestry were tested according 
to the method described by Phillips et al 12 for discrimination of 
components European, Asian, African and American ancient. The 
proportions of single and mixed populations were determined by 
ancestral populations of the CEPH and finally eingeinstrat and 
structure analysis of the alleles studied was applied, in order to 
make the correction of stratification13.
Statistical analysis: 
The Chi square test was applied to establish the Hardy-Weinberg 
equilibrium and comparisons between gene frequencies and the 
other qualitative variables. Quantitative variables were compared 
by Student t test. 
To determine the combined influence of various factors on the 
drug addiction was applied multinomial logistic regression model. 
95% confidence intervals were used and the level of statistical 
significance was set at p<0.05. For general statistical analysis 
software was used SPSS for Windows v.19.0; component analysis 
of ancestry between cases and controls were analyzed using the 
Structure software 3.1.3, and the R software, with the application 
engeinstrat.
Results
Demographic and clinical variables. There were no differences 
between the two groups with respect to age in years (controls: 
31±10 vs addicts: 31±10,3, p= 0.96), but in relation to the level 
of education (≤ 11 / ≥ 12 years) (controls: 40/80 vs. 107/13, p 
<0.001), marital status (married, cohabiting / separated-single) 
(controls: 46/74 vs. 24/96, p <0.001), right to security social (yes 
/ no) (controls: 113 / 7 vs 84/36, p <0.001) and family history of 
substance abuse (yes / no) (controls: 43/77 vs. 97/23, p <0.001). The 
age of onset in the consumption of coca derivatives or heroin was 
16.5±6 years (range 9-40 years), although it should be noted that 
almost all addicts had first experienced with other psychoactive; 
74.1% was addicted to cocaine derivatives, heroin 4.2% and 21.7% 
for both drugs, in addition 99.2% (119/120) of them used other 
illicit drugs, mainly marijuana, amphetamines and tranquilizers. 
Heroin use was concentrated in younger people (20±1.5 years), 
crack in older (36±10 years) and cocaine in an intermediate (25±7 
years).
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Table 1. Primers for amplification of fragments and probes for genotyping.
Gen SNP Forward (5´-3´) Reverse (5´-3´) SBE (5´-3´) Ref.
ABCB1 rs1045642 TATGTTGGCCTCCTTTGCTG GCTGAGAACATTGCCTATGG atgacgttgagtgGCCAATCACCTGTTCA This study
rs2032582 GCATAGTAAGCAGTAGGGAG GTCTGGACAAGCACTGAAAG ttttttttttttttttgtttacgttggatgacgttggatTGACTCACCTTCCCAG This study
rs1128503 TTTCTCACTCGTCCTGGTAG CACAGCCACTGTTTCCAACC ttttttttttttttttgtttacgttggatgacgttggatCTGGTAGATCTTGAAGGG This study
CYP2B6 rs34097093 CCACCCACCTCAACCTCCAA AACCCTCCACACACTCCACA gttggttgCCTCCTGTCCTCTCCC 10
rs35303484 TTCGTCTGTGTCTTACCCTC CTCTGCCCCTTTTGGGAAAC acgttgagtgGTCGACCATGGCGATTTTT 10
rs36060847 AGGAAGGATGAGGAAGGGGC ATTGTCTTTCTTTCCTATTCATCC ttggatgacgttgagtgctCTGGCGTTCGTGGGG 10
rs36079186 TCGGTCTGCCCATCTATAAA TGATTCTTCACATGTCTGCG gacgttggatgacgttgagtgCTCCTTTGCTGCCCTCAC 10
rs3745274 TCGGTCTGCCCATCTATAAA TGATTCTTCACATGTCTGCG atgacgttggatgacgttggatggttggattgTCTTGCTGGCACCCAAT 10
rs12721655 TGTGGAGTGTGTGGAGGGTT CTGGTGTCTGGGAAAGAAAT tttttttttttttttttttgtttacgttggatgacgttggatCCCCACCTTCCTCTTCCA 10
DBH rs1611115 ACAGGACCTTTGCCATCATC AAGCAGAATGTCCTGAAGGC tggatAGAGCAGTGCTCAGG This study
DRD2 rs1800497 CAACACAGCCATCCTCAAAG TGTGCAGCTCACTCCATCCT tttgttggatgacgttggatggttggatgCCTCAAAGTGCTGGTC This study
rs1799972 CAGTGCAATTGCTGGCGTTC GAAAAGTCTCGGTGCTCCTG ggttgAGTAGGCCTCTTCTATCCA This study
rs1799971 GGGTCAACTTGTCCCACTTA TGATGGCCGTGATCATGGAG gatgacgttggatgacgttgagtgGACTTCGGGATGGGA This study
DRD4 Exon3 VNTR FAM- GAAGGAGCAGGCACCGTGAGC ------- This study
SLC6A3 Int8 VNTR Yaquima -GGTGTAGGGAACGGCCTG AG CTGGAGGTCACGGCTCAAGG ------- This study




According to data from the population structure the ancestry 
component for cases and controls are Africa (0.1137 vs 0.1297), 
Europe (0.5268 vs 0.5308), East Asia(0.0100 vs 0.0110) and Native 
American (0.3495 vs 0.3284);  no significant difference (p =0.98) 
among  cases and controls was found.
Genetic markers of drug addiction: 
The SNPs  rs35979566, rs35303484, rs28399499, rs36060847, 
rs12721655, rs34097093 and rs36079186 of CYP2B6 gene, 
rs1799972 of OPRM1 gene and rs2032582 of ABCB1 gene were 
monomorphic in the studied samples. The Hardy-Weinberg 
equilibrium was confirmed with each of the genotypes of addicts 
and controls, except with the ABCB1 gene rs1128503 in the 
control group, so this marker was excluded from the analysis. The 
samples subjected to quality control by sequencing coincided with 
the previously assigned genotype. According to the allelic and 
genotypic distributions shown in Table 2, there were no significant 
differences between addicts and non addicts with respect to the 
studied polymorphisms of the OPRM1, DβH, DRD2, DRD4, 
SLC6A4 and CYP2B6 gene. By contrast, between addicts and 
controls significant  associations were found for Int8 VNTR 
SLC6A3 gene (p= 0.015, OR = 4.7 (1.34 -16.2)) and 3435C>T 
(rs1045642) ABCB1 gene (p= 0.0002, OR=2.4 (1.4 – 4.1)). These 
differences persisted when comparing separate consumers from 
coca or heroin (data not shown). However, for the Int8 VNTR 
in SLC6A3, the comparison of the 5R/5R genotype versus all 
the others displayed was not statistically significant after the 
Bonferroni correction for multiple testing (p= 0.16).   
The combined influence of various factors on drug addiction was 
assessed by multivariate analysis, using the condition of addict/
control as the dependent variable, and as covariates those that were 
significant in the bivariate analysis. According to the results shown 
in Table 3, the low level of education, separated-single marital 
status, the absence of social security, positive family history drug, 
carrier status of 6-R allelic variants of SLC6A3 gene and 3435CC 
genotype of ABCB1 gene, respectively, remain as independent 
factors associated with addiction heroin and/or derivatives of coca 
(cocaine or crack) in the patients in our study.
Discussion
Drug addiction is a multifactorial disease affected by 
psychological variables, physiological, pharmacological, genetic 
and environmental. A great deal of current research focuses on the 
search for factors that influence the vulnerability for the acquisition 
of addiction, for their persistence and propensity to relapse, which 
will result in a better scientific basis of prevention and treatment 
programs for drug addicts. According to the National Survey of 
Substance Abuse in Colombia (2008), last year 2.7% of surveyed 
(about 540,000 people) used illicit drugs.  Being marijuana and 
cocaine/crack the most widely used.  Respect to heroin, its abuse 
in the country is more recent and less known, the data suggest that 
this is already a social problems, especially if one considers that 
when a person starts their consumption can escalate into abuse 
and after the drug dependence more rapidly and intensely than for 
any other illegal drug. It is estimated, for example, that one in four 
people who try drugs end up addicted and the mortality among 
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Table 2. Genotypic and allelic distribution between addicts to heroin or coca derivatives and health controls.
Cases Controls Cases Controls
   n (%) HWEb      n (%) HWEb      n (%)    n (%)
OPRM1  rs1799971 A/A= 85 (70.8) 0.79  94 (79.0) 0.72 - A= 203(84.6) 212(89.1) -
A/G= 33(27.5) - 24(20.2) - - G= 37(15.4) 26(10.9) 0.18
G/G=   2(1.7) - 1(0.8) - 0.332 - - - -
DBH rs1611115 G/G= 63(52.5) 0.9 49(41.2) 0.62 - G= 172(71.7) 157(66.0) -
G/A= 46(38.3) - 59(49.6) - - A= 68(28.3) 81(34.0) 0.2
A/A= 11(9.2) - 11(9.2) - 0.187 - - - -
DRD2 rs1800497 G/G= 60(50.0) 0.91 56(47.1) 0.11 - G= 168(70.0) 170(71.4) -
G/A= 48(40.0) - 58(48.7) - - A= 72(30.0) 68(28.6) 0.76
A/A= 12(10.) - 5(4.2) - 0.138 - - - -
DRD4 VNTR exon3 S/S= 108(93.1) 0.31 110(97.3) 0.84 - S= 221(95.3) 222(98.2) 0.11
S/L= 5(4.3) - 2(1.8) - - L= 11(4.7) 4(1.8) -
L/L= 3(2.6) - 1(0.9) - 0.332 - - - -
SLC6A3 VNTR 8int 5R/5R= 3(2.5) 0.94 14(11.7) 0.33 - 5R= 42(17.5) 69(28.7) -
5R/6R= 36(30) - 41(34.2) - - 6R= 188(78.3) 167(69.6) -
6R/6R= 76(63.3) - 63(52.5) - - Othersc= 10(4.2) 4(1.7) 0.007
Otrosc= 5(4.2) - 2(1.7) - 0.015d - - - -
SLC6A4 5-HTTLPR S/S= 29(24.4) 0.99 38(32.2) 0.33 - S= 118(49.6) 127(53.8) -
S/L= 60(50.4) - 51(43.2) - - L= 120(50.4) 109(46.2) 0.36
L/L= 30(25.2) - 29(24.4) - 0.377 - - - -
ABCB1 rs1045642 C/C= 46(38.3) 0.18 19(16.0) 0.32 - C= 137(57.1) 109(45.8) -
C/T= 45(37.5) - 71(59.6) - - T= 103(42.9) 129(54.2) 0.02
T/T= 29(24.2) - 29(24.4) - 0.0002e - - - -
CYP2B6 rs3745274 G/G= 57(51.8) 0.4 54(52.9) 0.36 - G= 154(70.0) 144(70.6) -
G/T= 40(36.4) - 36(35.3) - - T= 66(30.0) 60(29.4) 0.92
T/T= 13(11.8) - 12(11.8) - 0.985 - - - -
a: Chi Square test for difference between addicts and non-addicts. b : Hardy-Weinberg Equilibrium. c: Genotype and alleles with frequency under 0.01 were grouped in a single class and analysis 
exclued d :For VTR 8 int in SLC6A4. that was not significant after the Bonferroni correction for multiple testing (P  value of 0.12) e: For rs1045642 in ABCB1 gen. was significant after the Bonferroni 






heroin users is 10-20 times higher than non-users matched for age 
and gender, and 12 times higher than the general population2. 
Many clinical and demographic findings of this study are 
consistent with several epidemiological reports of heroin and/
or coca derivatives such as age of onset (16.5±6 years), high 
proportion of individuals with a family history of drug abuse in 
first and second degree (80.8%), without a stable relationship 
(80%) and without social security (70%). In effect, numerous 
studies show that most people have become involved in the 
consumption of psychoactive substances adolescence early, when 
significantly increases the probability of risky behavior, including 
experimentation with psychoactive substances. On the other 
hand, personality disorders, stressful life events and emotional 
relationships negative, including parent-child relationships are 
predictors of addictive behavior14. In addition, although this study 
did not want to identify patterns of interaction between genes and 
environment, should not ignore the abundant evidence on the role 
of these interactions in the development of addictive behaviors and 
psychiatric disorders. 119 of the 120 addicts in this study said they 
consume more than one psychoactive drug, this confirms that the 
abuse of various drugs is the rule between consumers. Although 
this study also explored the psychiatric comorbidity, it is good to 
remember that psychiatric disorders are also very high among 
drug addicts, the most common mood disorders, posttraumatic 
stress and antisocial personality. 
As all addicts included in this study were residents of therapeutic 
communities and participated in rehabilitation programs based 
solely on abstinence, we should make some comments. Due 
to a better understanding of physiopathologic mechanisms of 
addictive disease, it is clear that no single therapeutic approach 
able to cover its many facets, is necessary multidisciplinary 
management, with two main therapeutic tools currently available: 
the pharmacological and psychosocial therapy. 
The latter is the therapy of choice for cocaine dependence, but 
many patients do not respond, the discovery of useful medicines 
is an emergency, so it has boosted the development of promising 
drugs that are currently in clinical trials. On the contrary, without 
ignoring the importance of psychosocial treatment, the drug of 
choice is the cornerstone of treatment for opioid dependence. 
So the “maintenance treatment” (suspension of heroin and 
substitute prescribed an opioid, usually methadone) should be 
prioritized, not the “detoxification” (stopping the drug, without 
replacement)15. From the point of view neurobiochemistry some 
neural circuits and neurotransmitter systems are important in 
the predisposition, development and maintenance of addictive 
behaviors. Is considered a risk factor for psychoactive substance 
abuse, the hypodopaminergic status in the reward circuitry of the 
limbic system, caused by some polymorphisms of genes related 
to dopamine 6,18 ,some authors speak of the reward deficiency 
syndrome, RDS, in which the drug addiction predisposition 
of individuals explained by: high rates of uptake of dopamine 
(DAT), high rate of degradation of dopamine (DβH) or low levels 
of dopamine receptors (DR)16.
The  allele int8-6R of VNTR in SLC6A3 gene is found in greater 
proportion in the group of drug addicts in this study (Table 3) 
which confirms this hypothesis can be explained as a phenotype 
with low dopaminergic tone tends to be offset by the use drugs 
that stimulate the reward system. Although this result agrees 
with others17,there is also evidence to the opposite result15 or no 
association between this polymorphism and heroin addiction 
or alcohol18. On the other hand, the 3435CC genotype of gene 
ABCB1 is associated with expression adequate levels of P-gp, the 
transporter that acts as a pump of exclusion and plays a key role 
in the disposition of xenobiotics in the CNS and other organs. It 
has been reported the association of the 3435C native allele with 
marijuana dependence19 and the effects of a variety of neurological 
and psychiatric drugs, among which are some opioids2. 
However, it is unclear whether cocaine or heroin are substrates 
of P-gp  and, to our knowledge, the influence of ABCB1 
polymorphisms on the brain disposition to cocaine or heroin has 
not been investigated so far. Some hypotheses may explain why 
3435CC genotype prevalent among drug users in this study; first, 
psychoactive drugs in the CNS of controls with the mutated allele 
(phenotype P-gp deficient) produces excessive and dysphoric 
levels of dopamine, functioning as a protective factor against abuse 
of psychoactive substances, similar to the action of disulfiram in 
cocaine addicts. Second, the increased efficiency of the transporter 
(P-gp competent phenotype) between wild genotype addicts 
cause euphoric effect of shorter duration, which produces a rapid 
abstinence syndrome and greater compulsion to continue use. The 
two hypotheses are not mutually exclusive, but both start from the 
premise that both cocaine and heroin are substrates of P-gp, which 
has not been shown yet. Allele rs1800497 (Taq1A G>A) of  DRD2 
gene results in a lower number of D2 receptors and one type of 
receptor with lower binding capacity of dopamine20. In this and 
other studies no relationship between this polymorphism and drug 
dependence21 were found. However most of the studies support 
an association of the mutated allele A with heroin abuse, alcohol, 
smoking and various aspects of addictive behavior21. The VNTR 
polymorphism of the DRD4 gene, coinciding with the results of 
this study, some authors have found no differences of allele S (2 
to 6 repeat) and L (7 or more repeat) among drug addicts and 
controls21. However, after a thorough review of scientific literature, 
McGeavy J 22 concluded that there was consistent evidence of the 
relationship of VNTR allele L with addictive behavior, explained 
by the fact that VNTR-L allele is associated with lower density 
receptors and reduced sensitivity to dopamine. Allele rs1611115 
(-1021C> T) DβH gene decreases the activity of the enzyme20, but 
evidence of the association of this polymorphism with addictive 
behavior is weak5. Several studies have reported positive association 
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Table 3. Logistic regression analysis of associated variables with 
addiction to heroin and/or coca derivatives.  
Variable P OR* (95%CI)*
Separated/single marital status       0.005 2.2 1.3 – 3.9
Low education                                  0.001 14 8.3 – 25
Without social security                     0.002 3.1 1.5 – 6.4 
Family history of addiction               0.001 5.6 3.4 – 9.4
Allelic variants:
SLC6A3  VNTR-Int8 6R        0.06 2.5 1.3 – 4.6
ABCB1  3435CC                  0.002 4.3 1.8 – 10.6
 * OR: odds ratio; (95%CI): 95% confidence interval.
24
of allele rs1799971 (118 A>G) of OPRM1 gene, encoding the μ 
opioid receptor, with heroin and alcohol addiction3, although in 
other research, including this, have not replicated these findings23. 
Also in our study significant differences in 5-HTTLPR genotypes 
S/S, S/L and L/L SLC6A4 gene between addicts and controls were 
found. For this marker the results are  also contradictory  because 
while in a study the SS genotype was associated with risk of abuse 
of cocaine24, other authors have reported a positive association of 
the variant L with various addictions7. 
Is necessary to emphasize some limitations of this study. First, the 
group of addicts studied does not represent all drug addicts, as 
it only included over 16 years, all of them had sought help and 
were interned in rehabilitation centers. Second, recognizing that 
gender is an important factor in substance abuse studies14,25, in 
this study, for logistical reasons,  only males were included, which 
excludes the possibility of finding gender-specific associations. 
Also cannot exclude the possibility of associations between other 
polymorphism of the genes studied and addictive disease, as this 
would require the complete sequencing of genes. It should also 
be recognized that some genetic markers reported in this study 
have also been linked with mental illness, which often coexist with 
drug addiction; this opens the real possibility that the association 
of genetic polymorphism is found with some underlying mental 
illness and not drug addiction. Equally is possible that other 
genes in linkage disequilibrium to those in this study are those 
actually associated with drug addiction. Discrepancies in the 
results of genetic studies related to drug addiction should not 
be surprising. The discrepancies in the results of genetic studies 
related to substance abuse are common. This is due largely to 
the difficulty in identifying risk biomarkers of disease as the 
drug dependence, result of complex interactions of genetic and 
environmental factors, which probably involves multiple genes 
and each of them makes only a modest contribution to total risk21. 
Consequently, the sample size limits the statistical power to detect 
small contributions from some markers studied. Finally we must 
recognize that the status of controls was established by self-report 
and therefore some people in the control group could have hidden 
or underestimated exposure to substances of abuse. Our findings 
provide preliminary evidence of the association between the 
ABCB1 polymorphism and heroin or cocaine dependence and the 
association between SLC6A3 and heroin or cocaine dependence 
was confirmed. These findings encourage future efforts in the 
search for functional polymorphism in and near the ABCB1 gene 
using a systemic approach in a larger sample.
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